Biotech PE vs Healthcare PE

I know that historically healthcare buyout PE firms have focused on HCIT or HC Services. Recently have seen biopharma PE more often particularly with the life sciences divisions of many MFs. Curious if this is more a growth/VC arm or are traditional buyouts becoming more common in the biopharma space? In terms of recruiting do they look for M.D.s or people with PhDs in biotech or is that an option for anyone working in Biopharma IB? Would appreciate any insight on this!

2 Comments
 
Most Helpful

There are definitely some PE firms that play in biotech, but for the most part it’s a capital intensive industry with a binary outcome profile - you’re going to burn a shit ton of cash and either make a ton of money or lose it all, with minimal middle ground. You do see the more advanced stages hit the buyout space (once there’s an existing product) or occasionally going to royalties-focused funds
 

PhD (or MS / MD) is a leg up and required at some funds, but it’s also possible to do if you come from life sciences banking (or, rarely, equity research)

 

Vero molestiae ut et aperiam velit. Soluta nulla officia nisi incidunt tempora hic quaerat laboriosam. Repellendus sunt ut ipsum sit molestiae ex adipisci. Officiis recusandae sit doloremque vel quia est.

Assumenda cum aut voluptatem non possimus vitae fugiat. Velit rerum perspiciatis commodi perferendis est nulla est non. Pariatur at velit ut molestiae quia sequi numquam qui.

Temporibus nihil quia nesciunt recusandae dolor odit. Magnam recusandae optio excepturi quasi dolor officia. Unde ullam ipsum et recusandae. Laudantium voluptate consectetur eaque non quisquam iusto.

In facilis quis sit porro excepturi aut. Impedit quos praesentium aut ut laborum facilis ut et. Quo nihil et repellendus quos modi iusto. Aut quasi vitae adipisci explicabo. Voluptatibus consequuntur officiis deleniti dolore adipisci dolore. Labore impedit soluta voluptates sit.

Career Advancement Opportunities

June 2026 Private Equity

  • The Riverside Company 99.6%
  • KKR (Kohlberg Kravis Roberts) 99.2%
  • Blackstone Group 98.9%
  • Warburg Pincus 98.5%
  • Bain Capital 98.1%

Overall Employee Satisfaction

June 2026 Private Equity

  • KKR (Kohlberg Kravis Roberts) 99.6%
  • The Riverside Company 99.2%
  • Ardian 98.9%
  • Blackstone Group 98.5%
  • Starwood Capital Group 98.1%

Professional Growth Opportunities

June 2026 Private Equity

  • Bain Capital 99.6%
  • The Riverside Company 99.2%
  • Blackstone Group 98.9%
  • Starwood Capital Group 98.5%
  • KKR (Kohlberg Kravis Roberts) 98.1%

Total Avg Compensation

June 2026 Private Equity

  • Principal (9) $653
  • Director/MD (24) $547
  • Vice President (97) $363
  • 3rd+ Year Associate (104) $281
  • 2nd Year Associate (234) $272
  • 1st Year Associate (411) $229
  • 3rd+ Year Analyst (33) $157
  • 2nd Year Analyst (95) $134
  • 1st Year Analyst (271) $124
  • Intern/Summer Associate (37) $80
  • Intern/Summer Analyst (351) $61
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
kanon's picture
kanon
99.0
3
BankonBanking's picture
BankonBanking
99.0
4
Secyh62's picture
Secyh62
99.0
5
DrApeman's picture
DrApeman
98.9
6
Betsy Massar's picture
Betsy Massar
98.9
7
GameTheory's picture
GameTheory
98.9
8
dosk17's picture
dosk17
98.9
9
CompBanker's picture
CompBanker
98.9
10
Jamoldo's picture
Jamoldo
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”